ES3028873T3 - Small molecules for the treatment of primary cancer and cancer metastasis - Google Patents

Small molecules for the treatment of primary cancer and cancer metastasis Download PDF

Info

Publication number
ES3028873T3
ES3028873T3 ES16737981T ES16737981T ES3028873T3 ES 3028873 T3 ES3028873 T3 ES 3028873T3 ES 16737981 T ES16737981 T ES 16737981T ES 16737981 T ES16737981 T ES 16737981T ES 3028873 T3 ES3028873 T3 ES 3028873T3
Authority
ES
Spain
Prior art keywords
cancer
compounds
cells
hydrogen
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16737981T
Other languages
English (en)
Spanish (es)
Inventor
Jean Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Application granted granted Critical
Publication of ES3028873T3 publication Critical patent/ES3028873T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES16737981T 2015-01-17 2016-01-15 Small molecules for the treatment of primary cancer and cancer metastasis Active ES3028873T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562104705P 2015-01-17 2015-01-17
PCT/US2016/013645 WO2016115487A1 (fr) 2015-01-17 2016-01-15 Petites molécules pour le traitement d'un cancer primaire et d'une métastase cancéreuse

Publications (1)

Publication Number Publication Date
ES3028873T3 true ES3028873T3 (en) 2025-06-20

Family

ID=56406469

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16737981T Active ES3028873T3 (en) 2015-01-17 2016-01-15 Small molecules for the treatment of primary cancer and cancer metastasis

Country Status (8)

Country Link
US (4) US10214529B2 (fr)
EP (1) EP3245204B1 (fr)
CN (1) CN107428753B (fr)
CA (2) CA3197570A1 (fr)
DK (1) DK3245204T3 (fr)
ES (1) ES3028873T3 (fr)
HK (1) HK1245778A1 (fr)
WO (1) WO2016115487A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1245778A1 (zh) * 2015-01-17 2018-08-31 Jean X. JIANG 用於治疗原发性癌症和癌症扩散的小分子
WO2019079691A1 (fr) * 2017-10-19 2019-04-25 Jean Jiang Petites molécules pour le traitement de troubles auto-immuns
CN109675037B (zh) * 2019-01-25 2021-09-14 南方医科大学 Atp及其受体在制备治疗自闭症药物中的应用
CN114524815B (zh) * 2022-02-23 2023-05-23 华南理工大学 一种8-烷氧基嘌呤衍生物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CA2565037A1 (fr) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Antagonistes du recepteur de l'adenosine a<sb>1</sb>
EP1805147B1 (fr) * 2004-09-30 2014-08-13 Janssen Pharmaceutica NV Modulateurs selectifs du recepteur d'androgene a base de derives benzimidazoliques
WO2009088518A1 (fr) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. Antagonistes du récepteur d'adénosine a2b pour le traitement du cancer
CN103827115A (zh) 2011-09-20 2014-05-28 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶化合物、组合物和使用方法
US20150297623A1 (en) * 2012-11-06 2015-10-22 The Board Of Regents Of The University Of Texas System Methods for treatment of primary cancer and cancer metastasis
HK1245778A1 (zh) * 2015-01-17 2018-08-31 Jean X. JIANG 用於治疗原发性癌症和癌症扩散的小分子

Also Published As

Publication number Publication date
US20190169190A1 (en) 2019-06-06
HK1245778A1 (zh) 2018-08-31
CA2977044A1 (fr) 2016-07-21
CN107428753B (zh) 2020-03-03
CA2977044C (fr) 2023-06-27
WO2016115487A1 (fr) 2016-07-21
US12325705B2 (en) 2025-06-10
US10214529B2 (en) 2019-02-26
EP3245204B1 (fr) 2025-04-30
US11680067B2 (en) 2023-06-20
US20210206769A1 (en) 2021-07-08
US20180009809A1 (en) 2018-01-11
CA3197570A1 (fr) 2016-07-21
US20230322782A1 (en) 2023-10-12
EP3245204A1 (fr) 2017-11-22
DK3245204T3 (da) 2025-05-12
CN107428753A (zh) 2017-12-01
EP3245204A4 (fr) 2018-10-03

Similar Documents

Publication Publication Date Title
US12325705B2 (en) Small molecules for the treatment of primary cancer and cancer metastasis
ES2705698T3 (es) Terapia de combinación para el tratamiento del cáncer que comprende eribulina y lenvatinib
JP6038921B2 (ja) デシタビン誘導体製剤
ES2893155T3 (es) Composición farmacéutica para inhibir el crecimiento de células madre de cáncer, que contiene un inhibidor de aldehído y un compuesto a base de biguanida
TWI522105B (zh) 偏亞砷酸鈉於治療癌疼痛及炎症之用途
KR20090005297A (ko) 암 치료를 위한 할로피루베이트의 효과적이고 안전한 투여 방법 및 이를 위한 조성물
US20150283237A1 (en) Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer
ES2745506T3 (es) Combinación antitumoral que comprende cabazitaxel y cisplatino
ES3038469T3 (en) Quinoline derivative and epirubicin used for soft tissue sarcoma combination therapy
US20150297623A1 (en) Methods for treatment of primary cancer and cancer metastasis
DK2262493T3 (en) METHODS OF TREATMENT WITH prolonged continuous infusion of Belinostat
ES2467968T3 (es) Regímenes de dosificación de un agente antitumoral que comprende un derivado de desoxicitidina
CN110709079B (zh) 包含1，2-萘醌衍生物化合物的实体癌或血液癌的预防或治疗用药物组合物
HK1240937B (zh) 用於治疗原发性癌症和癌症转移的小分子
HK1240937A1 (en) Small molecules for the treatment of primary cancer and cancer metastasis
WO2023275422A1 (fr) Composé de rithénium (iii) et de 2,2&#39;-bimidazole (runat-bi) et son utilisation thérapeutique
HK1152247B (en) Methods of treatment employing prolonged continuous infusion of belinostat